Cancer Immunotherapy Efficacy rely on Tumor Biology rather than Pathology: Consequences for Personalized Strategies

The lesson learned over the past 15 years is that cancer immunotherapies efficacy rely on tumor biological features (PD-L1, TMB, CD8, TLS,…)  rather than the histo-morphological description of the tumor tissue. However, still in 2025, we keep enrolling patients in clinical trials without looking at their drug target expression or their specific tumor biology. In this seminar, we will present how we are currently implementing fresh tissue explorations to enable patient selection and stratification in the context of prospective clinical trials in order to build personalized cancer immunotherapies.